PKC

Protein kinase C

PKC (Protein kinase C) is a family of protein kinase enzymes that are involved in controlling the function of otherproteins through the phosphorylation of hydroxyl groups of serine and threonine amino acid residues on these proteins. PKC enzymes in turn are activated by signals such as increases in the concentration of diacylglycerol (DAG) or calcium ions (Ca^{2+}). Hence PKC enzymes play important roles in several signal transduction cascades. The PKC family consists of 15 isozymes in humans: PKC-α (PRKCA), PKC-β1 (PRKCB), PKC-β2 (PRKCB), PKC-γ (PRKCG), PKC-δ (PRKCD), PKC-δ1 (PRKD1), PKC-δ2 (PRKD2), PKC-δ3 (PRKD3), PKC-ε (PRKCE), PKC-η (PRKCH), PKC-θ (PRKCQ), PKC-ι (PRKCI), PKC-ζ (PRKCZ), PK-N1 (PKN1), PK-N2 (PKN2), PK-N3 (PKN3). PKC is involved in receptor desensitization, in modulating membrane structure events, in regulating transcription, in mediating immune responses, in regulating cell growth, and in learning and memory. These functions are achieved by PKC-mediated phosphorylation of other proteins.

(-)-Indolactam V

(Indolactam V) Cat. No.: HY-12307

(-)-Indolactam V is a **PKC** activator, with K_is of 3.36 nM, 1.03 μM for η-CRD2 (PKCη surrogate peptide), γ-CRD2 (PKCγ surrogate peptide), and K_ds of 5.5 nM (η-C1B), 7.7 nM (ε-C1B), 8.3 nM (δ-C1B), 18.9 nM (β-C1A-long), 20.8 nM (α-C1A-long), 137 nM (β-C1B), 138 nM (γ-C1A),...



Purity: 98.75%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

(-)-Indolactam V-d8

(Indolactam V-d8) Cat. No.: HY-12307S

(-)-Indolactam V-d8 (Indolactam V-d8) is the deuterium labeled (-)-Indolactam V.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(±)-1,2-Diolein

(1,2-Dioleoyl-rac-glycerol) Cat. No.: HY-115767

(±)-1,2-Diolein (1,2-Dioleoyl-rac-glycerol) is a **PKC** activator. (±)-1,2-Diolein increases myotubes Ca^{2+} influx.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

1,2-Didecanoylglycerol

Cat. No.: HY-115769

1,2-Didecanoylglycerol, a synthetic diacylglycerol, is metabolized by platelets to 1,2-didecanoylphosphatidic acid (PA_{10}) and activates **protein kinase C (PKC)**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

1,2-Dimyristoyl-sn-glycerol

Cat. No.: HY-128468

1,2-Dimyristoyl-sn-glycerol is a saturated diacylglycerol and a weak second messenger for the activation of **PKC**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

1-Oleoyl-2-acetyl-sn-glycerol

Cat. No.: HY-131648

1-Oleoyl-2-acetyl-sn glycerol is a synthetic, cell permeable diacylgly cerol analog. 1-Oleoyl-2-acetyl-sn glycerol activates **calcium-dependent pro tein kinase C (PKC)** and induces the superoxide-production.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

1-Stearoyl-2-Arachidonoyl-d8-sn-Glycerol

Cat. No.: HY-131897S

1-Stearoyl-2-Arachidonoyl-d8-sn-Glycerol is the deuterium labeled 1-Stearoyl-2-arachidonoyl-sn-glycerol. 1-Stearoyl-2-arachidonoyl-sn-glycerol is a diacylglycerol (DAG) containing polyunsaturated fatty acids.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

1-Stearoyl-2-arachidonoyl-sn-glycerol

Cat. No.: HY-131897

1-Stearoyl-2-arachidonoyl-sn-glycerol is a diacylglycerol (DAG) containing polyunsaturated fatty acids. 1-Stearoyl-2-arachidonoyl-sn-glycerol can activate **PKC**.



Purity: 96.10%
Clinical Data: No Development Reported
Size: 5 mg15.50 mM * 500 μL in Methyl acetate,

A-3 hydrochloride

Cat. No.: HY-125957

A-3 hydrochloride is a potent, cell-permeable, reversible, ATP-competitive non-selective antagonist of various **kinases**. It against PKA (K_i=4.3 μM), casein kinase II (K_i=5.1 μM) and myosin light chain kinase (MLCK) (K_i=7.4 μM).



Purity: 99.67%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Afuresertib

(GSK2110183) Cat. No.: HY-15727

Afuresertib (GSK2110183) is an orally bioavailable, selective, ATP-competitive and potent pan-Akt kinase inhibitor with K_is of 0.08/2/2.6 nM for Akt1/Akt2/Akt3, respectively.



Purity: 99.54%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Afuresertib hydrochloride

(GSK2110183 hydrochloride) Cat. No.: HY-15727A

Afuresertib hydrochloride (GSK 2110183 hydrochloride) is an orally bioavailable, selective, ATP-competitive and potent pan-Akt kinase inhibitor with K_is of 0.08/2/2.6 nM for Akt1/Akt2/Akt3 respectively.



Purity: 98.02%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AS2521780

Cat. No.: HY-12663

AS2521780 is a novel **PKCθ** selective inhibitor with an IC_{50} of 0.48 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Aurora A/PKC-IN-1

Cat. No.: HY-144307

Aurora A/PKC-IN-1 (Compound 2e) is a potent dual inhibitor of **Aurora A (AurA)** and **PKC (α, β1, β2, and θ) kinases** with IC_{50}s of 6.9 nM and 16.9 nM for AurA and PKCα, respectively. Aurora A/PKC-IN-1 has antiproliferative activity in breast cancer cells and antimetastatic activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Aurothiomalate sodium

Cat. No.: HY-106381

Aurothiomalate sodium is a potent and selective oncogenic $PKC_ι$ signaling inhibitor.
Aurothiomalate sodium inhibits tumor cell proliferation and not cell apoptosis.
Aurothiomalate sodium is a potent **thioredoxin reductase (TrxR)** inhibitor.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Bisindolylmaleimide I

(GF109203X; Go 6850) Cat. No.: HY-13867

Bisindolylmaleimide I (GF109203X) is a highly selective, cell-permeable, and reversible protein kinase C (**PKC**) inhibitor with a K_i of 14 nM.



Purity: 99.03%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Bisindolylmaleimide II

(Bis II) Cat. No.: HY-108604

Bisindolylmaleimide II is a general inhibitor of all PKC subtypes.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bisindolylmaleimide IV

(Arcyriarubin A) Cat. No.: HY-108254

Bisindolylmaleimide IV (Arcyriarubin A) is a potent **protein kinase C (PKC)** inhibitor, with IC_{50}s ranging from 0.1 to 0.55 μM. Bisindolylmaleimide IV also inhibits PKA (IC_{50}=3.1-11.8μM).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Bisindolylmaleimide VIII acetate

(Ro 31-7549 acetate; Bis VIII acetate) Cat. No.: HY-129624A

Bisindolylmaleimide VIII acetate (Ro 31-7549 acetate) is a potent and selective **protein kinase C (PKC)** inhibitor with an IC_{50} of 158 nM for rat brain PKC.



Purity: 99.70%
Clinical Data: No Development Reported
Size: 5 mg

Bisindolylmaleimide X hydrochloride

(BIM-X hydrochloride; Ro31-8425 hydrochloride) Cat. No.: HY-108136A

Bisindolylmaleimide X hydrochloride (BIM-X hydrochloride) is a potent and selective **protein kinase C (PKC)** inhibitor. Bisindolylmaleimide X hydrochloride is a potent **cyclin-dependent kinase 2 (CDK2)** antagonist with an IC_{50} of 200 nM.



Purity: 99.35%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Bisindolylmaleimide XI hydrochloride

(Ro 32-0432; Ro 31-8830 hydrochloride) Cat. No.: HY-117610A

Bisindolylmaleimide XI hydrochloride (Ro 32-0432) is a potent, selective and orally active **PKC** inhibitor with IC_{50}s of 9 nM, 28 nM, 31 nM, 37 nM, and 108 nM for **PKCα**, **PKCβI**, **PKCβII**, **PKCγ**, and **PKCε**, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Bisindolylmaleimide XI-d6 hydrochloride

(Ro 32-0432-d6; Ro 31-8830-d6 hydrochloride) Cat. No.: HY-117610AS

Bisindolylmaleimide XI-d6 hydrochloride (Ro 32-0432-d6) is the deuterium labeled Bisindolylmaleimide XI hydrochloride.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BJE6-106

(B106) Cat. No.: HY-117800

BJE6-106 (B106) is a potent, selective 3rd generation **PKCδ** inhibitor with an **IC_{50}** of 0.05 μM and targets selectivity over classical PKC isozyme PKCα (IC_{50}=50 μM). BJE6-106 (B106) induces caspase-dependent **apoptosis**. BJE6-106 (B106) possesses tumor-specific effect.



Purity: 98.17%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Bryostatin 1

Cat. No.: HY-105231

Bryostatin 1 is a natural macrolide isolated from the bryozoan Bugula neritina and is a potent and central nervous system (CNS)-permeable **PKC** modulator.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 10 μg

Bryostatin 3

Cat. No.: HY-108602

Bryostatin 3, a macrocyclic lactone, is a **protein kinase C** activator, with a **K_i** of 2.75 nM. Bryostatin 3 can block 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibition of cell proliferation, yet did not block TPA-enhanced cell-substratum adhesion.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

C8-Ceramide

(N-Octanoyl-D-erythro-sphingosine) Cat. No.: HY-108391

C8-Ceramide (N-Octanoyl-D-erythro-sphingosine) is a cell-permeable analog of naturally occurring ceramides. C8-Ceramide has anti-proliferation properties and acts as a potent chemotherapeutic agent.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg

Calphostin C

(UCN-1028C) Cat. No.: HY-105416

Calphostin C is a potent and specific inhibitor of **protein kinase C**. Calphostin C is an antitumor antibiotic. Calphostin C has 1000 times more inhibitory to protein kinase C with an **IC_{50}** of 0.05 μM than other protein kinases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CC-90005

Cat. No.: HY-132304

CC-90005 is a potent, selective and orally active inhibitor of **protein kinase C-θ (PKC-θ)**, with an **IC_{50}** of 8 nM. CC-90005 shows selectivity for PKC-θ over PKC-δ (IC_{50}=4440 nM). CC-90005 can inhibit T cell activation by IL-2 expression.



Purity: 99.98%
Clinical Data: Phase 1
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Cercosporin

Cat. No.: HY-N6743

Cercosporin is produced by a plant pathogen, Cercosporakikuchii, and the elsinochromes, pigments of the elsinoe family of fungi.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

CGP-53353

(DAPH-7) Cat. No.: HY-108600

CGP-53353 (DAPH-7) is an potent **PKC** inhibitor with **IC_{50}**s of 0.41 mM and 3.8 mM for PKCβII and PKCβI, respectively. CGP-53353 can inhibit glucose-induced cell proliferation and **DNA synthesis** in AoSMC and A10 cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CGP60474

Cat. No.: HY-11009

CGP60474, a highly potent anti-endotoxemic agent, is a potent **cyclin-dependent kinase (CDK)** inhibitor (**IC_{50}** values are 26, 3, 4, 216, 10, 200 and 13 nM for CDK1/B, CDK2/E, CDK2/A, CDK4/D, CDK5/p25, CDK7/H and CDK9/T, respectively).



Purity: 98.70%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Chelerythrine

Cat. No.: HY-N2359

Chelerythrine is a natural alkaloid, acts as a potent and selective Ca^{2+}/phospholipid-dependent **PKC** antagonist, with an IC_{50} of 0.7 μM. Chelerythrine has antitumor, antidiabetic and anti-inflammatory activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Chelerythrine chloride

Cat. No.: HY-12048

Chelerythrine chloride is a potent, cell-permeable inhibitor of **protein kinase C**, with an IC_{50} of 660 nM. Chelerythrine chloride inhibits the **Bcl-XL-Bak BH3** peptide binding with IC_{50} of 1.5 μM and displaces Bax from Bcl-XL. Chelerythrine chloride induces **apoptosis** and **autophagy**.



Purity: 98.56%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CMPD101

Cat. No.: HY-103045

CMPD101 is a potent, highly selective and membrane-permeable small-molecule inhibitor of **GRK2/3** with IC_{50} of 18 nM and 5.4 nM, respectively.



Purity: 98.74%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg

CRT0066854

Cat. No.: HY-18713

CRT0066854 is a potent and selective atypical **PKC isoenzymes** inhibitor. CRT0066854 is against full-length (FL) **PKCι**, **PKCζ**, and **ROCK-II** kinases with IC_{50} values of 132 nM, 639 nM, and 620 nM, respectively.



Purity: 99.59%
Clinical Data: No Development Reported
Size: 1 mg

CRT0066854 hydrochloride

Cat. No.: HY-18713A

CRT0066854 hydrochloride is a potent and selective atypical **PKC**s inhibitor. CRT0066854 is against full-length (FL) **PKCι**, **PKCζ**, and **ROCK-II** kinases with IC_{50} values of 132 nM, 639 nM, and 620 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

D-erythro-Sphingosine (Erythrosphingosine; erythro-C18-Sphingosine; trans-4-Sphingenine)

Cat. No.: HY-101047

D-erythro-Sphingosine (Erythrosphingosine) is a very potent activator of **p32-kinase** with an EC_{50} of 8 μM, and inhibits **protein kinase C (PKC)**. D-erythro-Sphingosine (Erythrosphingosine) is also a **PP2A** activator.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

D-erythro-Sphingosine-d7 (Erythrosphingosine-d7; erythro-C18-Sphingosine-d7; trans-4-Sphingenine-d7)

Cat. No.: HY-101047S

D-erythro-Sphingosine-d7 (Erythrosphingosine-d7) is the deuterium labeled D-erythro-Sphingosine. D-erythro-Sphingosine (Erythrosphingosine) is a very potent activator of **p32-kinase** with an EC_{50} of 8 μM, and inhibits **protein kinase C (PKC)**.



Purity: >98%
Clinical Data: No Development Reported
Size: 500 μg

Daphnetin (7,8-Dihydroxycoumarin)

Cat. No.: HY-N0281

Daphnetin (7,8-dihydroxycoumarin), one coumarin derivative isolated from plants of the Genus Daphne, is a **protein kinase** inhibitor, with IC_{50}**s** of 7.67 μM, 9.33 μM and 25.01 μM for EGFR, PKA and PKC in vitro, respectively.



Purity: 99.21%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Daphnoretin (Dephnoretin; Thymelol)

Cat. No.: HY-N0699

Daphnoretin (Dephnoretin), isolated from Wikstroemia indica, possesses antiviral activity. Daphnoretin likes PMA, may direct activation of protein kinase C which in turn activated NADPH oxidase and elicited respiratory burst.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 20 mg

Darovasertib (LXS196; IDE196)

Cat. No.: HY-101569

Darovasertib (LXS196) is a potent, selective and orally active protein kinase C (**PKC**) inhibitor, with IC_{50} values of 1.9 nM, 0.4 nM and 3.1 μM for PKCα, PKCθ and GSK3β, respectively. Darovasertib has the potential for uveal melanoma research.



Purity: 99.68%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

DCP-LA

(FR236924) Cat. No.: HY-108599

DCP-LA (FR236924), a linoleic acid derivative, selectively and directly activates **PKCε**.

Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

DCPLA-ME

(DCPLA methyl ester) Cat. No.: HY-108599A

DCPLA-ME, the methyl ester form of DCPLA, is a potent **PKCε** activator for use in the treatment of neurodegenerative diseases.

Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Decursin

((+)-Decursin) Cat. No.: HY-18981

Decursin ((+)-Decursin) is a cytotoxic agent and a potent **protein kinase C** activator from the Root of Angelica gigas. Decursin inhibits tumor growth, migration, and invasion in gastric cancer by down-regulating CXCR7 expression.



Purity: 99.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Decursinol angelate

Cat. No.: HY-N4322

Decursinol angelate, a cytotoxic and **protein kinase C (PKC)** activating agent from the root of Angelica gigas, possesses anti-tumor and anti-inflammatory activities.



Purity: 99.54%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Delcasertib

(KAI-9803; BMS-875944) Cat. No.: HY-106262

Delcasertib (KAI-9803) is a potent and selective δ-protein kinase C (**δPKC**) inhibitor. Delcasertib (KAI-9803) could ameliorate injury associated with ischemia and reperfusion in animal models of acute myocardial infarction (MI).



Purity: 98.21%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 25 mg, 50 mg

Delcasertib hydrochloride

(KAI-9803 hydrochloride; BMS-875944 hydrochloride) Cat. No.: HY-106262B

Delcasertib (KAI-9803) hydrochloride is a potent and selective δ-protein kinase C (**δPKC**) inhibitor. Delcasertib (KAI-9803) hydrochloride could ameliorate injury associated with ischemia and reperfusion in animal models of acute myocardial infarction (MI).



Purity: 98.11%
Clinical Data: Phase 2
Size: 5 mg, 10 mg

Desmethylglycitein

(4',6,7-Trihydroxyisoflavone) Cat. No.: HY-N5072

Desmethylglycitein (4',6,7-Trihydroxyisoflavone), a metabolite of daidzein, sourced from Glycine max with antioxidant, and anti-cancer activities.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Enzastaurin

(LY317615) Cat. No.: HY-10342

Enzastaurin (LY317615) is a potent and selective **PKCβ** inhibitor with an IC_{50} of 6 nM, showing 6- to 20-fold selectivity over PKCα, PKCγ and PKCε.



Purity: 99.92%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Epsilon-V1-2

(ε-V1-2; EAVSLKPT) Cat. No.: HY-P0154

Epsilon-V1-2 (ε-V1-2), a PKCε-derived peptide, is a selective **PKCε** inhibitor. Epsilon-V1-2 inhibits the translocationof PKCε, but not α-, β-, and δPKC.



Purity: 98.18%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Fasudil

(HA-1077; AT877) Cat. No.: HY-10341A

Fasudil (HA-1077; AT877), is a nonspecific **RhoA/ROCK** inhibitor and also has inhibitory effect on protein kinases, with an K_i of 0.33 μM for ROCK1, IC_{50}s of 0.158 μM and 4.58 μM, 12.30 μM, 1.650 μM for ROCK2 and PKA, PKC, PKG, respectively.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Fasudil Hydrochloride

(HA-1077 Hydrochloride; AT-877 Hydrochloride) Cat. No.: HY-10341

Fasudil Hydrochloride (HA-1077 Hydrochloride; AT877 Hydrochloride), is a nonspecific **RhoA/ROCK** inhibitor and also has inhibitory effect on protein kinases, with an K_i of 0.33 μM for ROCK1, IC_{50}s of 0.158 μM and 4.58 μM, 12.30 μM, 1.650 μM for ROCK2 and PKA, PKC, PKG, respectively.



Purity: 99.91%
Clinical Data: Launched
Size: 10 mM × 1 mL, 200 mg, 500 mg

Go 6983

(Gö 6983; Goe 6983) Cat. No.: HY-13689

Go 6983 is a pan-PKC inhibitor against for **PKCα**, **PKCβ**, **PKCγ**, **PKCδ** and **PKCζ** with IC_{50} of 7 nM, 7 nM, 6 nM, 10 nM and 60 nM, respectively.



Purity: 98.01%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Go6976

Cat. No.: HY-10183

Go6976 is a Protein Kinase C (**PKC**) inhibitor, with an IC_{50} of 20 nM.



Purity: 99.34%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HA-100

Cat. No.: HY-100984

HA-100 is a potent **protein kinase** inhibitor, with IC_{50}s of 4 μM, 8 μM, 12 μM and 240 μM for **cGMP-dependent protein kinase (PKG)**, **cAMP-dependent protein kinase (PKA)**, **protein kinase C (PKC)** and **MLC-kinase**, respectively. HA-100 also used as a **ROCK** inhibitor.



Purity: 99.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

HA-100 hydrochloride

Cat. No.: HY-100984A

HA-100 hydrochloride is a potent **protein kinase** inhibitor, with IC_{50}s of 4 μM, 8 μM, 12 μM and 240 μM for cGMP-dependent protein kinase (**PKG**), cAMP-dependent protein kinase (**PKA**), protein kinase C (**PKC**) and **MLC-kinase**, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HBDDE

Cat. No.: HY-131305

HBDDE, a derivative of Ellagic acid, is an isoform-selective **PKCα** and **PKCγ** inhibitor with IC_{50}s of 43 μM and 50 μM, respectively. HBDDE shows selective for **PKCα/PKCγ** over PKCδ, PKCβI and PKCβII isozymes. HBDDE induces neuronal **apoptosis**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Hispidin

Cat. No.: HY-100618

Hispidin, a **PKC** inhibitor and a phenolic compound from Phellinus linteus, has been shown to possess strong anti-oxidant, anti-cancer, anti-diabetic, and anti-dementia properties.



Purity: 99.57%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Hu7691

Cat. No.: HY-132302

Hu7691 is an orally active, selective **Akt** inhibitor with IC_{50}s of 4.0 nM, 97.5 nM, 28 nM for Akt1, Akt2 and Akt3, respectively. Hu7691 inhibits tumor growth and enables decrease of cutaneous toxicity in mice.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Hu7691 free base

Cat. No.: HY-132302A

Hu7691 free base is an orally active, selective **Akt** inhibitor with IC_{50}s of 4.0 nM, 97.5 nM, 28 nM for Akt1, Akt2 and Akt3, respectively. Hu7691 free base inhibits tumor growth and enables decrease of cutaneous toxicity in mice.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Hypocrellin A

Cat. No.: HY-N2575

Hypocrellin A, a naturally occurring **PKC** inhibitor, has many biological and pharmacological properties, such as antitumour, antiviral, antibacterial, and antileishmanial activities. Hypocrellin A is a promising photosensitizer for anticancer photodynamic therapy (PDT).



Purity: 99.55%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Ingenol

((-)-Ingenol)

Cat. No.: HY-N0865

Ingenol is a **PKC** activator, with a K_i of 30 μM, with antitumor activity.



Purity: 98.17%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Ingenol 3,20-dibenzoate

Cat. No.: HY-137295

Ingenol 3,20-dibenzoate is a potent **protein kinase C (PKC)** isoform-selective agonist.



Purity: 99.31%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Ingenol Mebutate

(Ingenol 3-angelate; PEP005)

Cat. No.: HY-B0719

Ingenol Mebutate is an active ingredient in Euphorbia peplus, acts as a potent **PKC** modulator, with K_is of 0.3, 0.105, 0.162, 0.376, and 0.171 nM for PKC-α, PKC-β, PKC-γ, PKC-δ, and PKC-ε, respectively, and has antiinflammatory and antitumor activity.



Purity: 99.07%
Clinical Data: Launched
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Ionomycin

(SQ23377)

Cat. No.: HY-13434

Ionomycin (SQ23377) is a potent, selective **calcium ionophore** and an antibiotic produced by Streptomyces conglobatus. Ionomycin (SQ23377) is highly specific for divalent cations (Ca>Mg>Sr=Ba). Ionomycin (SQ23377) promotes **apoptosis**.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 10 mg (14.1 mM * 1 mL in Ethanol)

Ionomycin calcium

(SQ23377 calcium)

Cat. No.: HY-13434A

Ionomycin calcium (SQ23377 calcium) is a potent, selective **calcium ionophore** and an antibiotic produced by Streptomyces conglobatus. Ionomycin calcium (SQ23377 calcium) is highly specific for divalent cations (Ca>Mg>Sr=Ba). Ionomycin (SQ23377) promotes **apoptosis**.



Purity: 98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

K-252a

(SF2370; Antibiotic K 252a; Antibiotic SF 2370)

Cat. No.: HY-N6732

K-252a, a staurosporine analog, inhibits **protein kinase**, with IC_{50} values of 470 nM, 140 nM, 270 nM, and 1.7 nM for PKC, PKA, Ca^{2+}/calmodulin-dependent kinase type II, and phosphorylase kinase, respectively.



Purity: 99.45%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

K-252b

Cat. No.: HY-N6734

K-252b, an indolocarbazole isolated from the actinomycete Nocardiopsis, is a **PKC** inhibitor. K-252b can be used to inhibit extracellular kinases of cells in culture because it can't pass through cell membrane freely .



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg

K-252c

Cat. No.: HY-N6736

K-252c, a staurosporine analog isolated from Nocardiopsis sp., is a cell-permeable **PKC** inhibitor, with an IC_{50} of 2.45 μM. K-252c induces apoptosis in human chronic myelogenous leukemia cancer cells. K-252c also inhibits β-lactamase, chymotrypsin, and malate dehydrogenase.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Kobophenol A

Cat. No.: HY-126419

Kobophenol A, an oligomeric stilbene, blocks the interaction between the ACE2 receptor and S1-RBD with an IC_{50} of 1.81 μM and inhibits **SARS-CoV-2** viral infection in cells with an EC_{50} of 71.6 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

KT5823

Cat. No.: HY-N6791

KT5823, a selective the cGMP-dependent protein kinase (**PKG**) inhibitor with an K_i value of 0.23 μM, it also inhibits **PKA** and **PKC** with K_i values of 10 μM and 4 μM, respectively.



Purity: 99.68%
Clinical Data: No Development Reported
Size: 100 μg

Leucosceptoside A

Cat. No.: HY-N8018

Leucosceptoside A is a phenylethanoid glycoside with anti-hyperglycemic and anti-hypertensive activities. Leucosceptoside A shows inhibitory activity against **α-glucosidase** and **PKCα** (IC_{50} of 19.0 μM).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Malantide

Cat. No.: HY-P1597

Malantide is a synthetic dodecapeptide derived from the site phosphorylated by **cAMP-dependent protein kinase (PKA)** on the β-subunit of phosphorylase kinase.

RTKRSGSVYEPLKI

Purity: 98.56%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Malantide TFA

Cat. No.: HY-P1597A

Malantide TFA is a synthetic dodecapeptide derived from the site phosphorylated by **cAMP-dependent protein kinase (PKA)** on the β-subunit of phosphorylase kinase.

RTKRSGSVYEPLKI (TFA salt)

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mezerein

Cat. No.: HY-N7466

Mezerein is a **PKC** activator that exhibits antileukemic properties. Mezerein inhibits the growth of yeast expressing PKC alpha (IC_{50}=1190 nM), PKC beta1 (IC_{50}=908 nM), and PKC delta (IC_{50}=141 nM) but not of yeast expressing PKC.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Midostaurin

(PKC412; CGP 41251)

Cat. No.: HY-10230

Midostaurin (PKC412; CGP 41251) is a multi-targeted protein kinase inhibitor which inhibits **PKCα/β/γ**, **Syk**, **Flk-1**, **Akt**, **PKA**, **c-Kit**, **c-Fgr**, **c-Src**, **FLT3**, **PDFRβ** and **VEGFR1/2** with IC_{50}s ranging from 22-500 nM.



Purity: 99.89%
Clinical Data: Launched
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Mitoxantrone

(mitozantrone)

Cat. No.: HY-13502

Mitoxantrone is a **topoisomerase II** inhibitor; also inhibits protein kinase C (**PKC**) activity with an IC_{50} of 8.5 μM.



Purity: 98.28%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

Mitoxantrone dihydrochloride

(mitozantrone dihydrochloride)

Cat. No.: HY-13502A

Mitoxantrone dihydrochloride is a **topoisomerase II** inhibitor; also inhibits protein kinase C (**PKC**) activity with an IC_{50} of 8.5 μM.



Purity: 99.55%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

Mitoxantrone-d8

Cat. No.: HY-13502S

Mitoxantrone-d8 (mitozantrone-d8) is the deuterium labeled Mitoxantrone. Mitoxantrone is a **topoisomerase II** inhibitor and also inhibits protein kinase C (**PKC**) activity with an IC_{50} of 8.5 μM.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Myelin Basic Protein

(MHP4-14)

Cat. No.: HY-P1821

Myelin Basic Protein (MHP4-14), a synthetic peptide comprising residues 4-14 of myelin basic protein, is a very selective PKC substrate (K_m=7 μM).

QKRPSQRSKYL

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Myelin Basic Protein TFA

(MHP4-14 TFA)

Cat. No.: HY-P1821A

Myelin Basic Protein (MHP4-14) TFA, a synthetic peptide comprising residues 4-14 of myelin basic protein, is a very selective PKC substrate (K_m=7 μM).

QKRPSQRSKYL (TFA salt)

Purity: 95.02%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

N-Desmethyltamoxifen

Cat. No.: HY-129099

N-Desmethyltamoxifen is the major metabolite of tamoxifen in humans. N-Desmethyltamoxifen, a poor antiestrogen, is a ten-fold more potent **protein kinase C (PKC)** inhibitor than Tamoxifen.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

N-Desmethyltamoxifen hydrochloride

Cat. No.: HY-129099A

N-Desmethyltamoxifen hydrochloride is the major metabolite of tamoxifen in humans. N-Desmethyltamoxifen, a poor antiestrogen, is a ten-fold more potent **protein kinase C (PKC)** inhibitor than Tamoxifen.



Purity: 99.62%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

O-Desmethyl Midostaurin

(CGP62221; O-Desmethyl PKC412)

Cat. No.: HY-129491

O-Desmethyl Midostaurin (CGP62221; O-Desmethyl PKC412) is the active metabolite of Midostaurin (HY-10230) via cytochrome P450 liver enzyme metabolism. O-Desmethyl Midostaurin can be used as an indicator for Midostaurin metabolism in vivo.



Purity: 95.48%
Clinical Data: No Development Reported
Size: 5 mg

p32 Inhibitor M36

(M36)

Cat. No.: HY-124718

p32 inhibitor M36 (M36) is a **p32** mitochondrial protein inhibitor, which binds directly to p32 and inhibits p32 association with LyP-1.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Pep2m, myristoylated

(Myr-Pep2m)

Cat. No.: HY-P1399

Pep2m, myristoylated (Myr-Pep2m) is a cell-permeable peptide. Pep2m, myristoylated can disrupt the protein kinase ζ (PKMζ) downstream targets, **N-ethylmaleimide-sensitive factor/glutamate receptor subunit 2 (NSF/GluR2) interactions**.

{Myr}-KRMKVAKNAQ

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pep2m, myristoylated TFA

(Myr-Pep2m TFA)

Cat. No.: HY-P1399A

Pep2m, myristoylated TFA (Myr-Pep2m TFA) is a cell-permeable peptide. Pep2m, myristoylated TFA can disrupt the protein kinase ζ (PKMζ) downstream targets, **N-ethylmaleimide-sensitive factor/glutamate receptor subunit 2 (NSF/GluR2) interactions**.

{Myr}-KRMKVAKNAQ (TFA salt)

Purity: 99.77%
Clinical Data: No Development Reported
Size: 5 mg

PF-03622905

Cat. No.: HY-139466

PF-03622905 is a potent and ATP-competitive **PKC** inhibitor with **IC_{50}**s of 5.6 nM, 14.5 nM, 13 nM, 37.7 nM, and 74.1 nM for **PKCα**, **PKCβI**, **PKCβII**, **PKCγ**, and **PKCθ**, respectively. PF-03622905 shows high specificity for PKC over other protein kinases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PF-04577806

Cat. No.: HY-139467

PF-04577806 is a potent, selective and ATP competitive **PKC** inhibitor. PF-04577806 shows potent inhibitory activity towards **PKCα**, **PKCβI**, **PKCβII**, **PKCγ**, and **PKCθ** with **IC_{50}**s of 2.4 nM, 8.1 nM, 6.9 nM, 45.9 nM, and 29.5 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PF-4950834

Cat. No.: HY-122011

PF-4950834 is a potent, selective, orally bioavailable, ATP-competitive **rho kinase** inhibitor with **IC_{50}** values of 8.35 nM and 33.12 nM against ROCK2 and ROCK1, respectively. PF-4950834 inhibits neutrophil migration.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Phorbol 12,13-dibutyrate

(Phorbol dibutyrate; PDBu)

Cat. No.: HY-18985

Phorbol 12,13-dibutyrate (Phorbol dibutyrate) is a **PKC** activator and a potent skin tumor promoter.



Purity: 98.28%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Phorbol 12-myristate 13-acetate

(PMA; TPA; Phorbol myristate acetate) Cat. No.: HY-18739

Phorbol 12-myristate 13-acetate (PMA), a phorbol ester, is a dual **SphK** and **protein kinase C (PKC)** activator. Phorbol 12-myristate 13-acetate is a NF-κB activator. Phorbol 12-myristate 13-acetate induces differentiation in THP-1 cells.



Purity: 99.66%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg

PKC β pseudosubstrate

Cat. No.: HY-P1286

PKC β pseudosubstrate is a selective cell-permeable inhibitor of **PKC**.

Sequence 1:CRQIKIWFQNRRMKWKK
Sequence 1':CRFARKGALRQKNV
(Disulfide bridge:Cys1-Cys1')

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PKC β pseudosubstrate TFA

Cat. No.: HY-P1286A

PKC β pseudosubstrate TFA is a selective cell-permeable inhibitor of **PKC**.

Sequence 1:CRQIKIWFQNRRMKWKK
Sequence 1':CRFARKGALRQKNV
(Disulfide bridge:Cys1-Cys1') (TFA salt)

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PKC-IN-1

Cat. No.: HY-16903

PKC-IN-1 is a potent, ATP-competitive and reversible inhibitor of conventional **PKC** enzymes with K_is of 5.3 and 10.4 nM for human PKCβ and PKCα, and IC_{50}s of 2.3, 8.1, 7.6, 25.6, 57.5, 314, 808 nM for PKCα, PKCβI, PKCβII, PKCθ, PKCγ, PKC mu and PKCε, respectively.



Purity: 99.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PKC-iota inhibitor 1

Cat. No.: HY-126146

PKC-iota inhibitor 1 (compound 19) is a **protein kinase C-iota (PKC-ι)** inhibitor with an IC_{50} value of 0.34 μM.



Purity: 98.73%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PKC-theta inhibitor

Cat. No.: HY-112681

PKC-theta inhibitor is a selective PKC-θinhibitor, with an IC_{50} of 12 nM.



Purity: 99.75%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PKC-theta inhibitor 1

Cat. No.: HY-126328

PKC-theta inhibitor 1 is the **PKCθ** inhibitor with an K_i value of 6 nM, inhibits IL-2 production in vivo with an IC_{50} of 0.19 μM. PKC-theta inhibitor 1 demonstrates a reduction of symptoms in a mouse model of multiple sclerosis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PKCβ inhibitor 1

Cat. No.: HY-13335

PKCβ inhibitor 1 is a potent, ATP-competitive, and selective **PKCβ** inhibitor with IC_{50}s of 21 and 5 nM for human PKCβ1 and PKCβ2, respectively. PKCβ inhibitor 1 exhibits selectivity of more than 60-fold in favor of PKCβ2 relative to other PKC isozymes (PKCα, PKCγ, and PKCε).



Purity: 98.21%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg, 5 mg, 10 mg

Procyanidin A1

(Proanthocyanidin A1) Cat. No.: HY-N2344

Procyanidin A1 (Proanthocyanidin A1) is a procyanidin dimer, which inhibits degranulation downstream of protein kinase C activation or Ca^{2+} influx from an internal store in RBL-213 cells. Procyanidin A1 has antiallergic effects.



Purity: 99.19%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Protein Kinase C (19-31)

(PKC (19-31)) Cat. No.: HY-P1746

Protein Kinase C (19-31), a peptide inhibitor of **protein kinase C (PKC)**, derived from the pseudo-substrate regulatory domain of PKCa (residues 19-31) with a serine at position 25 replacing the wild-type alanine, is used as protein kinase C substrate peptide for testing...

RFARKGALRQKNV

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Protein Kinase C (19-31) (TFA)

(PKC (19-31) (TFA))

Cat. No.: HY-P1746A

Protein Kinase C (19-31) TFA, a peptide inhibitor of **protein kinase C (PKC)**, derived from the pseudo-substrate regulatory domain of PKCa (residues 19-31) with a serine at position 25 replacing the wild-type alanine, is used as protein kinase C substrate peptide for testing...

RFARKGALRQKNV (TFA salt)

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Protein Kinase C (19-36)

Cat. No.: HY-P1401

Protein Kinase C (19-36) is a pseudosubstrate peptide inhibitor of **protein kinase C (PKC)**, with an IC_{50} of 0.18 μM.

RFARKGALRQKNVHEVKN

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Protein kinase inhibitor H-7

Cat. No.: HY-131900

Protein kinase inhibitor H-7 is a potent inhibitor of **protein kinase C (PKC)** and **cyclic nucleotide dependent protein kinase**, with a K_i of 6 μM for PKC.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PS315

Cat. No.: HY-124308

PS315, a derivative of PS48 (HY-15967), is an allosteric **PKC** inhibitor by binding to the PIF-pocket of aPKC and inducing a displacement of the active site residue Lys111. PS315 inhibits the full-length and catalytic domain constructs of PKC_ζ (IC_{50}=10 μM) and PKC_η (IC_{50}=30 μM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Psychosine

(Galactosylsphingosine)

Cat. No.: HY-136490

Psychosine (Galactosylsphingosine), a substrate of the galactocerebrosidase (GALC) enzyme, is a potential biomarker for Krabbe disease.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

R 59-022

(DKGI-I; Diacylglycerol kinase inhibitor I)

Cat. No.: HY-107613

R 59-022 (DKGI-I) is a **diacylglycerol kinase** inhibitor (IC_{50}=2.8 μM). R 59-022 is a **5-HTR** antagonist, and activates **protein kinase C (PKC)**.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

R 59-022-d5

(DKGI-I-d5; Diacylglycerol kinase inhibitor I-d5)

Cat. No.: HY-107613S

R 59-022-d5 (DKGI-I-d5) is the deuterium labeled R 59-022. R 59-022 (DKGI-I) is a **diacylglycerol kinase** inhibitor (IC_{50}=2.8 μM). R 59-022 is a **5-HTR** antagonist, and activates **protein kinase C (PKC)**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

R59949

Cat. No.: HY-108355

R59949 is a pan **diacylglycerol kinase (DGK)** inhibitor with an IC_{50} of 300 nM. R59949 strongly inhibits the activity of type I DGK α and γ and moderately attenuates the activity of type II DGK θ and κ.



Purity: 97.01%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ro 31-8220

(Bisindolylmaleimide IX)

Cat. No.: HY-13866A

Ro 31-8220 is a potent **PKC** inhibitor, with IC_{50}s of 5, 24, 14, 27, 24 and 23 nM for PKCα, PKCβI, PKCβII, PKCγ, PKCε and rat brain PKC, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ro 31-8220 mesylate (Ro 31-8220 methanesulfonate; Bisindolylmaleimide IX mesylate)

Cat. No.: HY-13866

Ro 31-8220 mesylate is a potent **PKC** inhibitor, with IC_{50}s of 5, 24, 14, 27, 24 and 23 nM for PKCα, PKCβI, PKCβII, PKCγ, PKCε and rat brain PKC, respectively.



Purity: 99.28%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

Ro 32-0432 hydrochloride

Cat. No.: HY-108601A

Ro 32-0432 hydrochloride is a potent, selective, ATP-competitive and orally active **PKC** inhibitor. The IC_{50} values of Ro 32-0432 hydrochloride for **PKCα**, **PKCβI**, **PKCβII**, **PKCγ** and **PKCε** are 9.3 nM, 28 nM, 30 nM, 36.5 nM and 108.3 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Rottlerin

(Mallotoxin; NSC 56346; NSC 94525)

Cat. No.: HY-18980

Rottlerin, a natural product purified from Mallotus Philippinensis, is a specific **PKC** inhibitor, with IC_{50} values for PKCδ of 3-6 μM, PKCα,β,γ of 30-42 μM, PKCε,η,ζ of 80-100 μM.



Purity: 98.02%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg

Roy-Bz

Cat. No.: HY-111364

Roy-Bz is a selecive **PKCδ** activator. Roy-Bz potently inhibits the proliferation of colon cancer cells by inducing a PKCδ-dependent mitochondrial apoptotic pathway involving caspase-3 activation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ruboxistaurin

(LY333531)

Cat. No.: HY-10195

Ruboxistaurin (LY333531) is an orally active, selective **PKC beta** inhibitor (K_i=2 nM). Ruboxistaurin exhibits ATP dependent competitive inhibition of PKC beta I with an IC_{50} of 4.7 nM. Ruboxistaurin inhibits PKC beta II with an IC_{50} of 5.9 nM.



Purity: 98.03%
Clinical Data: Phase 3
Size: 5 mg, 10 mg, 25 mg

Ruboxistaurin hydrochloride

(LY333531 hydrochloride)

Cat. No.: HY-10195B

Ruboxistaurin (LY333531) hydrochloride is an orally active, selective **PKC beta** inhibitor (K_i=2 nM). Ruboxistaurin hydrochloride exhibits ATP dependent competitive inhibition of PKC beta I with an IC_{50} of 4.7 nM.



Purity: 99.84%
Clinical Data: Launched
Size: 5 mg

Ruboxistaurin-d6 hydrochloride

Cat. No.: HY-10195BS

Ruboxistaurin-d6 (LY333531-d6) hydrochloride is the deuterium labeled Ruboxistaurin hydrochloride. Ruboxistaurin (LY333531) hydrochloride is an orally active, selective **PKC beta** inhibitor (K_i=2 nM).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg, 10 mg

Safingol

(L-threo-dihydrosphingosine)

Cat. No.: HY-112384

Safingol is a lyso-sphingolipid PKC (protein kinase C) inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sangivamycin

(NSC 65346; BA-90912)

Cat. No.: HY-118384

Sangivamycin (NSC 65346), a nucleoside analog, is a potent inhibitor of **protein kinase C (PKC)** with an K_i of 10 μM. Sangivamycin has potent antiproliferative activity against a variety of human cancers.



Purity: 97.06%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

SB-218078

Cat. No.: HY-107407

SB-218078 is a potent, selective, ATP-competitive and cell-permeable **checkpoint kinase 1 (Chk1)** inhibitor that inhibits **Chk1** phosphorylation of cdc25C with an IC_{50} of 15 nM. SB-218078 is less potently inhibits **Cdc2** (IC_{50} of 250 nM) and **PKC** (IC_{50} of 1000 nM).



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SC-9

(NCM 119)

Cat. No.: HY-100934

SC-9 is a **PKC** activator in the presence of Ca^{2+}.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sotrastaurin

(AEB071)

Cat. No.: HY-10343



Sotrastaurin (AEB071) is a potent and orally-active pan-**PKC** inhibitor, with K_is of 0.22 nM, 0.64 nM, 0.95 nM, 1.8 nM, 2.1 nM and 3.2 nM for PKCθ, PKCβ, PKCα, PKCη, PKCδ and PKCε, respectively.

Purity: 99.89%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Sphingosine (d14:1)

(Tetradecasphing-4-enine)

Cat. No.: HY-118442



Sphingosine (d14:1) (Tetradecasphing-4-enine), a sphingolipid, is a potent **Protein kinase C (PKC)** inhibitor. Sphingosine (d14:1) prevents its interaction with sn-1,2-diacylglycerol (DAG)/Phorbol esters.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Spisulosine

(ES-285)

Cat. No.: HY-13626



Spisulosine (ES-285) is an antiproliferative (antitumoral) compound of marine origin. Spisulosine inhibits the growth of the prostate PC-3 and LNCaP cells through intracellular ceramide accumulation and **PKCζ** activation.

Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Staurosporine

(Antibiotic AM-2282; STS; AM-2282)

Cat. No.: HY-15141



Staurosporine is a potent, ATP-competitive and non-selective inhibitor of protein kinases with IC_{50}s of 6 nM, 15 nM, 2 nM, and 3 nM for **PKC**, **PKA**, **c-Fgr**, and **Phosphorylase kinase** respectively. Staurosporine also inhibits **TAOK2** with an IC_{50} of 3 μM. Staurosporine is an apoptosis inducer.

Purity: 99.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg

TAS-301

Cat. No.: HY-18965



TAS-301 is an inhibitor of smooth muscle cell migration and proliferation, and inhibits **PKC** activation induced by PDGF.

Purity: 99.50%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TCS 21311

(NIBR3049)

Cat. No.: HY-108264



TCS 21311 (NIBR3049) is a potent, highly selective **JAK3** inhibitor with an IC_{50} of 8 nM, it displays >100-fold selectivity over JAK1, JAK2 and TYK2. TCS 21311 (NIBR3049) inhibits **PKCα**, **PKCθ**, and **GSK3β** with IC_{50}s of 13, 68, and 3 nM, respectively.

Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Teleocidin A1

(Lyngbyatoxin A)

Cat. No.: HY-118834



Teleocidin A1 (Lyngbyatoxin A), a highly toxic skin irritant, is a potent activator of protein kinase C **(PKC)**. Teleocidin A1 shows antiproliferative activity against HeLa cancer cells (IC_{50}=9.2 nM).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TPPB

Cat. No.: HY-12359



TPPB is a cell-permeable benzolactam-derived protein kinase C (**PKC**) activator with a K_i of 11.9 nM.

Purity: 99.81%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

UCN-02

(7-epi-Hydroxystaurosporine)

Cat. No.: HY-108262



UCN-02 (7-epi-Hydroxystaurosporine) is a selective **protein kinase C (PKC)** inhibitor produced by Streptomyces strain N-12, with IC_{50}s of 62 nM and 250 nM for PKC and protein kinase A (PKA), respectively.

Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Valrubicin

(AD-32)

Cat. No.: HY-13772



Valrubicin is a chemotherapy agent, inhibits TPA- and PDBu-induced **PKC** activation with IC_{50}s of 0.85 and 1.25 μM, respectively, and has antitumor and antiinflammatory activity.

Purity: 99.60%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Verbascoside

(Acteoside; Kusaginin; TJC160)

Cat. No.: HY-N0021

Verbascoside is isolated from Lantana camara, acts as an ATP-competitive inhibitor of **PKC**, with an IC_{50} of 25 μM, and has antitumor, anti-inflammatory and antineuropathic pain activity.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

VTX-27

Cat. No.: HY-112782

VTX-27 is a selective protein kinase C θ **(PKC θ)** inhibitor, with K_is of 0.08 nM and 16 nM for PKC θ and PKC δ.



Purity: 99.64%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ZIP

Cat. No.: HY-P1284

ZIP is a selective peptide inhibitor of **PKMζ**. ZIP injections can block the impairment in morphine conditioned place preference induced.

{Myr-Ser}-IYRRGARRWRKL

Purity: 99.62%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

ZIP TFA

Cat. No.: HY-P1284A

ZIP TFA is a selective peptide inhibitor of **PKMζ**. ZIP TFA injections can block the impairment in morphine conditioned place preference induced.

{Myr-Ser}-IYRRGARRWRKL (TFA salt)

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

[Ala107]MBP(104-118)

Cat. No.: HY-P1289A

[Ala107]MBP(104-118) is an noncompetitive peptide inhibitors of **protein kinase C (PKC)**, with IC_{50}s ranging from 46-145 μM.

GKGAGLSLSRFSWGA

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

[Ala107]MBP(104-118) TFA

Cat. No.: HY-P1289B

[Ala107]MBP(104-118) TFA is an noncompetitive peptide inhibitors of **protein kinase C (PKC)**, with IC_{50}s ranging from 46-145 μM.

GKGAGLSLSRFSWGA (TFA salt)

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

[Ala113]MBP(104-118)

Cat. No.: HY-P1289

[Ala113]MBP(104-118) is an noncompetitive peptide inhibitors of **protein kinase C (PKC)**, with IC_{50}s ranging from 28-62 μM.

GKGRGLSLSAFSWGA

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

[Ala113]MBP(104-118) TFA

Cat. No.: HY-P1289C

[Ala113]MBP(104-118) TFA is an noncompetitive peptide inhibitors of **protein kinase C (PKC)**, with IC_{50}s ranging from 28-62 μM.

GKGRGLSLSAFSWGA (TFA salt)

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ζ-Stat

(NSC37044)

Cat. No.: HY-123979

ζ-Stat (NSC37044) is a specific and atypical **PKC-ζ** inhibitor, with an IC_{50} of 5 μM. ζ-Stat can reduce melanoma cell lines proliferation and induce apoptosis, and has antitumor activity in vitro.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

ζ-Stat trisodium

(NSC37044 trisodium)

Cat. No.: HY-123979A

ζ-Stat trisodium (NSC37044 trisodium) is a specific and atypical **PKC-ζ** inhibitor, with an IC_{50} of 5 μM. ζ-Stat trisodium can reduce melanoma cell lines proliferation and induce apoptosis, and has antitumor activity in vitro.



Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg